As well as opening its new Dublin biotech facility, the pharma company has recently begun construction on an expansion at its Carlow site.
MSD Ireland is today (1 November) officially opening its new biotech facility in Swords, Co Dublin.
The company has invested more than $1bn in the Dublin site since construction began in 2018. It already plays an important role in the manufacturing of the company’s biologics-based medicines, including immuno-oncology medicines.
Liam Dunne, MSD Biotech Dublin site head, said the company is looking forward to “delivering life-saving medication to patients all over the world”.
“Thanks to our new state-of-the-art facility, we will be able to do so at speed and scale,” he said.
“We have a number of open roles that will provide significant opportunities for employees to be a part of a pivotal, global hub for MSD’s biologics-based medicines,” said Dunne.
Speaking at the official opening of the site, An Taoiseach Micheál Martin paid tribute to MSD’s legacy in Ireland. “This investment is a vote of confidence in the talent of our workforce, and Ireland’s reputation as a cradle for biopharma innovation.”
Robert M Davis, CEO and president of MSD, added that Ireland plays “an integral role” in the company.
“Our ongoing investment in Ireland, including this state-of-the-art facility in Swords, is a testament to our commitment to the country and our talented colleagues in Ireland,” Davis concluded.
The pharma company has had a presence in Ireland for several decades and employs around 3,000 people across its six Irish sites. In recent years, the pharma company has invested more than $4bn in its Irish operations.
In August of this year, MSD said it was going to create 100 new jobs as part of a major expansion of its Carlow site.
10 things you need to know direct to your inbox every weekday. Sign up for the Daily Brief, Silicon Republic’s digest of essential sci-tech news.